Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:3:25-38.
doi: 10.2147/CMR.S8759. Epub 2010 Dec 30.

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies

Gina M Mantia-Smaldone  1 , Robert P Edwards, Anda M Vlad
Affiliations

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies

Gina M Mantia-Smaldone et al. Cancer Manag Res. 2011.

Abstract

With advances in surgical techniques and chemotherapeutic agents, mortality rates from epithelial ovarian cancer (EOC) have slightly decreased over the last 30 years. However, EOC still ranks as the most deadly gynecologic cancer with an overall 5-year survival rate of 45%. Prognosis is especially disappointing for women with platinum-resistant disease, where 80% of patients will fail to respond to available therapies. Emerging treatment strategies have sub-sequently focused on targets which are integral to tumor growth and metastasis. In this review, we will focus on those innovative agents currently under investigation in clinical trials.

Keywords: angiogenesis; growth factors; immunotherapy; ovarian cancer; platinum-resistant; targeted therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–249. - PubMed
    1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–2529. - PubMed
    1. Gadducci A, Landoni F, Maggino T, et al. Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. Int J Gynecol Cancer. 1997;7(1):78–83. - PubMed
    1. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161–S192. - PubMed
    1. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994;12(9):1748–1753. - PubMed